very good post.
OS numbers will never be definitive enough , ie, enough for a deal, with low numbers of patients.
Hence the need for Ph 2b studies.
(Very good management that we are not in Ph 3.)
proving correlation of antibody levels, with tumour reduction, and survival, as per this announcement will add great weight to legitimacy for BP, for a deal ( when we see(ie what I expect..with the increased dosage) antibody levels in the current running trial)
very good post.OS numbers will never be definitive enough , ie,...
-
- There are more pages in this discussion • 122 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.9¢ |
Change
0.001(2.08%) |
Mkt cap ! $364.4M | |||
| Open | High | Low | Value | Volume |
| 4.8¢ | 5.0¢ | 4.8¢ | $220.0K | 4.512M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 133532 | 4.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.0¢ | 4779371 | 27 |
View Market Depth
| Last trade - 11.19am 07/10/2024 (20 minute delay) ? |
| IMU (ASX) Chart |